John Hussman's UTHR Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 0 shares of United Therapeutics Corporation (UTHR) worth $0, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in UTHR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2017, adding 25,500 shares. Largest reduction occurred in Q4 2013, reducing 224,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +468,001 | Add 0.00% | 468,000 | $65.82 |
| Q3 2013 | -110,000 | Reduce 23.50% | 358,000 | $78.85 |
| Q4 2013 | -224,000 | Reduce 62.57% | 134,000 | $113.08 |
| Q3 2014 | -84,000 | Reduce 62.69% | 50,000 | $128.64 |
| Q1 2015 | -25,000 | Reduce 50.00% | 25,000 | $172.44 |
| Q4 2015 | -25,000 | Sold Out | 0 | $0.00 |
| Q1 2017 | +25,500 | New Buy | 25,500 | $135.37 |
| Q2 2017 | -250 | Reduce 0.98% | 25,250 | $129.74 |
| Q3 2017 | -250 | Reduce 0.99% | 25,000 | $117.20 |
| Q4 2017 | -15,000 | Reduce 60.00% | 10,000 | $147.90 |
| Q1 2018 | -10,000 | Sold Out | 0 | $0.00 |
| Q1 2019 | +25,000 | New Buy | 25,000 | $117.36 |
| Q3 2019 | -15,000 | Reduce 60.00% | 10,000 | $79.80 |
| Q4 2019 | -10,000 | Sold Out | 0 | $0.00 |
| Q3 2020 | +25,500 | New Buy | 25,500 | $101.02 |
| Q4 2020 | -15,300 | Reduce 60.00% | 10,200 | $151.76 |
| Q1 2021 | +600 | Add 5.88% | 10,800 | $167.22 |
| Q2 2021 | -3,600 | Reduce 33.33% | 7,200 | $179.44 |
| Q3 2021 | -4,100 | Reduce 56.94% | 3,100 | $184.52 |
| Q4 2021 | -500 | Reduce 16.13% | 2,600 | $216.15 |
| Q1 2022 | -2,600 | Sold Out | 0 | $0.00 |
| Q2 2023 | +9,300 | New Buy | 9,300 | $220.75 |
| Q3 2023 | -9,300 | Sold Out | 0 | $0.00 |
| Q3 2024 | +6,300 | New Buy | 6,300 | $358.35 |
| Q4 2024 | +2,100 | Add 33.33% | 8,400 | $352.84 |
| Q1 2025 | +4,200 | Add 50.00% | 12,600 | $308.27 |
| Q2 2025 | +2,100 | Add 16.67% | 14,700 | $287.35 |
| Q3 2025 | -14,700 | Sold Out | 0 | $0.00 |
John Hussman's United Therapeutics Corporation Investment FAQs
John Hussman first purchased United Therapeutics Corporation (UTHR) in Q2 2013, acquiring 468,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held United Therapeutics Corporation (UTHR) for 34 quarters since Q2 2013.
John Hussman's largest addition to United Therapeutics Corporation (UTHR) was in Q2 2013, adding 468,000 shares worth $30.8 M.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 0 shares of United Therapeutics Corporation (UTHR), valued at approximately $0.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.00% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in United Therapeutics Corporation (UTHR) was 468,000 shares, as reported at the end of Q2 2013.